Novartis: Good quarterly margins but significant miss at the top-line level

BUY, Fair Value CHF110 (+21%)
News published on October Tuesday 27, 2015
Share on

Mixed numbers today for Novartis which reported Q3 figures. Although margins are ahead of expectations and mainly reflect good cost control and favourable mix effect in Pharmaceuticals (higher growth in Specialty Care + GSK Oncology booking effect), the miss at the top-line level is very significant. Nothing to specifically worry about but the 3% difference to expectations should translate into a negative share price reaction as core EPS at USD1.27 is also USD0.02-0.03 below estimates.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities